Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by SHIOZAWA, S.
Right arrow Articles by SHIOZAWA, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SHIOZAWA, S.
Right arrow Articles by SHIOZAWA, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 British Society for Rheumatology

research-article

A PRELIMINARY STUDY ON THE INTERFERON-{alpha} TREATMENT FOR XEROSTOMIA OF SJÖGREN'S SYNDROME

S. SHIOZAWA*,, I. MORIMOTO*, Y. TANAKA{dagger} and K. SHIOZAWA{dagger}

*Department of Medicine, Third Division, Kobe University School of Medicine 7-5 Kusunokicho, Chuoku, Kobe 650, Japan
{dagger}Department of Medicine and Rheumatology, Kakogawa National Hospital Kakogawa, Japan

Correspondence to: *Correspondence to S. Shiozawa

We studied the therapeutic effect of interferon-{alpha} on the xerostomia of Sjögren's syndrome by injecting 1x106 units of interferon-{alpha} intramuscularly once weekly. Saliva production was quantitated by the Saxon test. Variation of saliva production measured at monthly intervals during the 3-month period prior to administration of interferon-{alpha} was within ±0.30 g/2 min. After administration of interferon-{alpha}, saliva production increased to greater than 0.30 g/2 min in six patients, and the increase was statistically significant by the paired t-test (P=0.002). The result suggests a beneficial effect of this agent in increasing the saliva production of patients with primary Sjögren's syndrome.

KEY WORDS: Sjögren's syndrome, Interferon-{alpha}, Xerostomia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
S Yamada, K Mori, K Matsuo, A Inukai, Y Kawagashira, and G Sobue
Interferon alfa treatment for Sjogren's syndrome associated neuropathy
J. Neurol. Neurosurg. Psychiatry, April 1, 2005; 76(4): 576 - 578.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Centola, G. Wood, D. M. Frucht, J. Galon, M. Aringer, C. Farrell, D. W. Kingma, M. E. Horwitz, E. Mansfield, S. M. Holland, et al.
The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators
Blood, May 15, 2000; 95(10): 3223 - 3231.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
M. Izumi, K. Eguchi, H. Nakamura, Y. Takagi, Y. Kawabe, and T. Nakamura
Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjogren's syndrome
Ann Rheum Dis, August 1, 1998; 57(8): 464 - 469.
[Abstract] [Full Text]

Home page
 Ann Rheum DisHome page
M. García-Carrasco, M. Ramos, R. Cervera, J. Font, J. Vidal, F. J Muñoz, C. Miret, G. Espinosa, and M. Ingelmo
Hepatitis C virus infection in `primary' Sjogren's syndrome: prevalence and clinical significance in a series of 90 patients
Ann Rheum Dis, March 1, 1997; 56(3): 173 - 175.
[Abstract] [Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.